In Tondo, Manila's most densely populated district, a community health worker hands a mother a single dose of ceftriaxone for her 4-year-old son, who has been febrile for five days. The nurse does not draw blood for culture. She does not ask about vaccination status. She follows the clinic's standing protocol: fever lasting more than three days in this neighborhood is typhoid until proven otherwise, and ceftriaxone is what they stock.

This scene repeats daily across Metro Manila's informal settlements—Baseco, Estero de Vitas, the railway track communities—where typhoid remains endemic and antibiotic resistance is rising. The World Health Organization lists ceftriaxone as a "reserve" antibiotic, meant only for confirmed multidrug-resistant infections when oral options fail. Yet in Manila's barangay health centers, it has become the empiric drug of choice for suspected typhoid. The disconnect between global stewardship guidelines and frontline practice is not a knowledge gap; it is a policy gap, shaped by payer rules, procurement constraints, and the absence of routine vaccination in the places that need it most.

Why Manila's Public Clinics Stock a Third-Line Antibiotic First

Every barangay health center in Manila carries ceftriaxone. It is on the Philippine essential medicines list, procured in bulk by the Department of Health, and supplied free to public clinics. The drug is cheap—roughly US$ 1–2 per vial—and stable at room temperature. For a clinic serving hundreds of patients daily with no laboratory, ceftriaxone offers a simple one-shot solution. The alternative—oral azithromycin—costs about US$ 1–2 per course, but requires adherence to a 5–7 day regimen and is not always in stock.

The WHO's AWaRe classification groups ceftriaxone in the "reserve" category, alongside carbapenems and colistin. Reserve antibiotics are supposed to be last-line agents, used only when all other options have failed. In practice, Manila's public clinics use it as a first-line empiric therapy for suspected typhoid. A 2023 audit by the Philippine Department of Health found that roughly 60% of ceftriaxone prescriptions in urban health centers were for acute febrile illness, with no microbiologic confirmation. The drug's overuse is a textbook driver of resistance.

Clinics justify the practice by pointing to local resistance patterns. Surveillance data from the Research Institute for Tropical Medicine shows that around 80% of Salmonella Typhi isolates from Manila are resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole—the traditional first-line drugs. Fluoroquinolone resistance is also high, hovering near 70% for nalidixic acid. With few oral options left, ceftriaxone becomes the default. But the logic is circular: using ceftriaxone widely creates selective pressure for ceftriaxone-resistant strains, which have already been reported in neighboring countries.

The situation mirrors a pattern seen in other low- and middle-income settings, where the line between "access" and "reserve" antibiotics blurs under real-world constraints. A similar dynamic was described in a 2023 study by Klein et al. in The Lancet Global Health, which found that reserve antibiotics are frequently used as first-line therapy in settings without diagnostic capacity. In Manila, the gap between what the evidence recommends and what the system can deliver is measured in centimeters of rain during monsoon season.

The Deadly Gap in Typhoid Vaccination Coverage

Typhoid is a vaccine-preventable disease. The typhoid conjugate vaccine (TCV) received WHO prequalification in 2017, and studies in India and Malawi have shown it reduces incidence by roughly 80–90% in endemic settings. The Philippines introduced TCV into its national immunization program in 2023, but only in selected regions with high reported incidence—mostly in Mindanao. Metro Manila, including the slums of Tondo and Baseco, was not included in the initial rollout.

The exclusion was not based on disease burden. A 2022 serosurvey in Tondo estimated that roughly 2–3% of children under 5 had recent or current typhoid infection, comparable to rates in the rollout regions. The decision was logistical: the Department of Health prioritized areas with existing cold-chain capacity and lower population mobility. But in Manila's slums, where families move frequently and health records are fragmented, the logistical argument cuts both ways—these are precisely the populations that benefit most from routine vaccination.

Private-sector TCV is available in Manila for roughly 500–1000 PHP (about US$ 9–18) per dose. For a family earning 300 PHP a day, that is prohibitive. Public health centers offer no routine typhoid immunization, and there is no catch-up campaign planned for urban poor communities. The result is a coverage gap that leaves the most exposed populations unprotected, while the vaccine sits in refrigerators in regions with lower transmission risk.

The WHO's Strategic Advisory Group of Experts has recommended TCV introduction in all countries with a high burden of typhoid, defined as more than 100 cases per 100,000 population per year. Manila's slums likely exceed that threshold, but no one has measured it precisely because surveillance is weak. The absence of data becomes a reason for inaction. Meanwhile, the vaccine's price has dropped to roughly US$ 2–3 per dose through Gavi, but the Philippines is not a Gavi-eligible country. The national immunization program must fund its own procurement, and budgets are tight.

How Payer Rules Distort Antibiotic Choice

PhilHealth, the Philippine national health insurer, reimburses hospitals and clinics through case rates—fixed payments for specific diagnoses. The typhoid case rate, as of late 2024, covers a hospital admission with intravenous antibiotics, typically ceftriaxone. The rate is roughly 8,000–10,000 PHP (US$ 145–180), which covers the cost of a 3–5 day stay. Outpatient management with oral antibiotics is not separately reimbursed, and the case rate does not cover a blood culture if it is not done.

This reimbursement structure creates a perverse incentive. A physician who prescribes oral azithromycin for uncomplicated typhoid may not trigger a PhilHealth claim, leaving the patient to pay out-of-pocket for the drug and follow-up. If the same physician admits the patient and gives intravenous ceftriaxone, the hospital can claim the case rate, covering both the drug and the bed. The financial logic pushes clinicians toward the more expensive, more resistance-prone option.

Similar distortions have been documented in other contexts. A 2022 analysis in Health Affairs described how private insurers covering drug cost caps can lead to overuse of high-cost medications when lower-cost alternatives exist. In the Philippines, the problem is compounded by the fact that PhilHealth does not require culture confirmation for the typhoid case rate. A clinical diagnosis suffices, so there is no financial incentive to pursue microbiologic testing. The system effectively subsidizes empirical ceftriaxone use.

Reforming the case rate is not simple. PhilHealth argues that raising the rate for outpatient care would increase administrative costs and could encourage overdiagnosis. But the current approach also encourages overuse of a reserve antibiotic. A middle-ground option would be to bundle the case rate with a requirement for blood culture, or to create a separate outpatient case rate for uncomplicated typhoid that covers oral antibiotics and a rapid diagnostic test. Without such reforms, the financial logic will continue to work against stewardship.

Manila Slums as Reservoirs of Resistant Salmonella

Tondo is a study in density. Roughly 70,000 people per square kilometer live in a warren of narrow alleys, elevated shanties, and open drainage canals. The Pasig River, which borders the district, receives untreated sewage from upstream communities and overflows during monsoon rains. A 2024 study published in the Philippine Journal of Microbiology sampled stool from 500 residents of Tondo and found that roughly 30% of carriers harbored Salmonella Typhi strains resistant to at least three antibiotic classes. The study was small and not nationally representative, but it aligns with trends across Southeast Asia.

Flooding is the critical transmission vector. During the June-to-November monsoon season, streets in Baseco and Estero de Vitas regularly submerge under ankle-deep water mixed with sewage. Children play in these puddles. Households store drinking water in open containers. A single contaminated water source can infect an entire block. The bacteria survive in water for weeks, and the cycle of infection-reinfection sustains endemic circulation.

Household transmission is also significant. In overcrowded homes, where 6–10 people share a single room, hygiene practices are difficult to maintain. A chronic carrier—often an older adult with gallstones—can shed Salmonella for years without symptoms. In Tondo, a 2023 survey found that roughly 5% of households had at least one member who was a long-term carrier. These asymptomatic carriers are invisible to the health system, but they keep the pathogen circulating.

The combination of overcrowding, poor sanitation, and limited access to clean water creates an epidemiological niche where resistant strains can emerge and persist. Unlike hospital outbreaks, which can be contained with infection control measures, community transmission in slums is diffuse and continuous. Antibiotic use in one household creates selection pressure that affects the entire neighborhood. Without improvements in basic infrastructure—piped water, sewage treatment, drainage—the reservoir will remain, and resistance will continue to evolve.

What a Culture-Based Approach Would Require

A blood culture is the gold standard for typhoid diagnosis. It costs roughly 800–1200 PHP (US$ 15–22) in a private laboratory—about a week's wages for a minimum-wage worker. Most public health centers in Manila do not have microbiology labs. Specimens must be transported to tertiary hospitals like the Research Institute for Tropical Medicine or the Philippine General Hospital, a process that takes 1–2 days. By the time the result comes back, the patient has often recovered or worsened, and the clinician has already committed to a treatment course.

Empiric ceftriaxone avoids this diagnostic delay. For a febrile child in Tondo, waiting 48 hours for a culture result is not practical. The clinician must decide on the spot, and the safest decision—given the local resistance profile—is ceftriaxone. But this safety comes at a cost. Each unnecessary ceftriaxone dose adds to the selective pressure that drives resistance. A 2022 modeling study from the University of the Philippines estimated that reducing empiric ceftriaxone use by 30% in Manila could delay the emergence of ceftriaxone-resistant typhoid by roughly 5–8 years.

Point-of-care diagnostics could bridge the gap. Rapid antigen tests for typhoid, such as the Typhidot and Tubex, are available and cost roughly 200–400 PHP (US$ 4–7). But their sensitivity is limited—around 70–80% in field studies—and they cannot distinguish between active infection and past exposure. The WHO does not recommend them for routine diagnosis. More promising are PCR-based tests, but they require equipment and trained personnel that are absent in barangay health centers.

Surveillance data from the Research Institute for Tropical Medicine shows that ceftriaxone resistance among Salmonella Typhi isolates in Manila has risen from roughly 2% in 2015 to near 8% in 2024. The trend is slow but consistent. A culture-based approach would detect these cases earlier and allow targeted therapy with carbapenems or azithromycin, but the system is not set up to do so. The diagnostic gap is not a technology problem; it is an investment problem. Building microbiology capacity in urban health centers would require sustained funding and training, neither of which is currently prioritized.

Cheaper Alternatives That Could Turn the Tide

Azithromycin is the most promising oral alternative for uncomplicated typhoid. The WHO recommends it as a first-line option in areas with fluoroquinolone resistance. A 5-day course costs roughly 50–100 PHP (US$ 1–2) in public pharmacies. It is well-tolerated, requires no injection, and has shown clinical efficacy in trials from Nepal and Bangladesh. Yet it is not widely stocked in Manila's health centers. The Department of Health's essential medicines list includes azithromycin, but procurement is inconsistent, and clinics often run out.

Resistance to azithromycin is emerging in Asia. A 2023 study from Pakistan reported azithromycin resistance in roughly 5% of Salmonella Typhi isolates. In India, the figure is around 2–3%. In the Philippines, systematic surveillance is lacking, but a 2024 case series from the Research Institute for Tropical Medicine identified three patients with reduced susceptibility to azithromycin. The drug is not a magic bullet; it is a finite resource that must be stewarded carefully.

Other oral options have fallen by the wayside. Gatifloxacin, a fluoroquinolone that showed promise against typhoid, was withdrawn from many markets in the 2000s due to dysglycemia side effects. Fosfomycin and carbapenems are effective but remain too expensive for routine use—fosfomycin costs roughly 500–1000 PHP per course, and carbapenems require intravenous administration and hospitalization. The pipeline for new oral typhoid antibiotics is thin. The last novel class approved for typhoid was the fluoroquinolones, in the 1980s.

Given the limitations of existing drugs, the most sustainable strategy is prevention. The typhoid conjugate vaccine is effective, safe, and becoming cheaper. A targeted vaccination campaign in Manila's slums—combined with improvements in water and sanitation—could reduce the need for antibiotics altogether. But that requires political will and funding that has not materialized. As one clinician in Tondo told me, "We are treating the same children every year. We are not stopping the transmission."

Policy Fixes That Start With the PhilHealth Case Rate

Reforming the typhoid case rate is the most direct lever available to policymakers. If PhilHealth restructured the rate to cover outpatient management with oral antibiotics—say, 3,000 PHP for a 5-day course of azithromycin plus a follow-up visit—clinics would have a financial incentive to avoid hospitalization and intravenous drugs. The savings from reduced hospital admissions could offset the cost of the new rate. A 2024 cost-effectiveness analysis from the University of the Philippines estimated that such a policy could save the health system roughly 20–30% per typhoid episode while reducing ceftriaxone use by an estimated 40%.

Including typhoid conjugate vaccine in the national immunization program for urban slum areas is another obvious step. The Department of Health has already purchased TCV for select regions; expanding to Manila would require an additional roughly 50 million PHP (US$ 900,000) for vaccine procurement, plus operational costs for outreach. That is a small fraction of the cost of treating resistant infections. A single case of extensively drug-resistant typhoid, requiring carbapenems and prolonged hospitalization, can cost the system over 100,000 PHP.

Point-of-care diagnostics could be subsidized through PhilHealth, with a separate case rate for culture-confirmed typhoid that includes a higher reimbursement. This would create a financial incentive for clinics to send blood cultures, generating the surveillance data needed to guide treatment guidelines. In parallel, the Philippine Department of Health could link PhilHealth reimbursements to antimicrobial stewardship compliance, as has been done in Thailand and South Africa. Hospitals that overprescribe reserve antibiotics could face reduced payments.

None of these fixes are easy. They require coordination between the Department of Health, PhilHealth, local government units, and international partners. They require investment in laboratory infrastructure and training. They require political will to prioritize a disease that is often invisible—typhoid does not generate the headlines that dengue or COVID-19 do. But the alternative is to continue the current trajectory, where a third-line antibiotic becomes a first-line crutch, and resistance slowly erodes the last effective treatments available to the urban poor.

The path forward demands a shift from reactive treatment to proactive prevention. Without reforms in payer rules, vaccine deployment, and diagnostic infrastructure, the cycle of resistance will persist. The child in Tondo will continue to receive ceftriaxone, the fever will break, but the bacteria will keep adapting. The question is whether policymakers will act before the next line of defense fails.

This article is for informational purposes only and does not constitute medical advice. Readers should consult a qualified healthcare professional for diagnosis and treatment decisions.